Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDH1 Peptide Vaccine in IDH1R132H-Mutated Gliomas
NCT02454634Phase 1Completed
- Sponsor
- National Center for Tumor Diseases
- Start
- Jun 2015
- Primary completion
- Sep 2017
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PEPIDH1M in glioma, sponsored by National Center for Tumor Diseases. Primary endpoints: Regime Limiting Toxicity at 15 months and Immunogenicity of IDH1 peptide vaccine at 15 months. Started Jun 2015; status: completed.
02
Drugs
PEPIDH1M
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02454634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02454634.